NO20061561L - Aerosolformuleringer for avlevering av dihydroergotamin til den systemiske sirkulasjon via pulmonaer inhalering - Google Patents

Aerosolformuleringer for avlevering av dihydroergotamin til den systemiske sirkulasjon via pulmonaer inhalering

Info

Publication number
NO20061561L
NO20061561L NO20061561A NO20061561A NO20061561L NO 20061561 L NO20061561 L NO 20061561L NO 20061561 A NO20061561 A NO 20061561A NO 20061561 A NO20061561 A NO 20061561A NO 20061561 L NO20061561 L NO 20061561L
Authority
NO
Norway
Prior art keywords
dihydroergotamine
aerosol formulations
delivery
via pulmonary
systemic circulation
Prior art date
Application number
NO20061561A
Other languages
English (en)
Inventor
Richard M Pavkov
Original Assignee
Map Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Map Pharmaceuticals Inc filed Critical Map Pharmaceuticals Inc
Publication of NO20061561L publication Critical patent/NO20061561L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Farmasøytiske aerosolformuleringer av dihyodroergotamin, eller farmasøytisk akseptable salter av denne, for administrering som tørrpulver eller drivstoff suspensjoner via pulmonar aerosol eller nesespray inhalasjon. Slike formuleringer kan anvendes forbehandling av ulike sykdomsstadier, tilstander, inkludert men ikke begrenset til, migrene hodepine. Dihydroergotamin partiklene produseres ved anvendelse av en superkritisk fiuidprosess. Aerosolformuleringene beskrevet har overlegen stabilitet, renhet og omfatter partikler av innåndbar størrelse særlig egnet for pulmonær avlevering.
NO20061561A 2003-09-10 2006-04-06 Aerosolformuleringer for avlevering av dihydroergotamin til den systemiske sirkulasjon via pulmonaer inhalering NO20061561L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50193803P 2003-09-10 2003-09-10
PCT/US2004/029632 WO2005025506A2 (en) 2003-09-10 2004-09-10 Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation

Publications (1)

Publication Number Publication Date
NO20061561L true NO20061561L (no) 2006-06-09

Family

ID=34312325

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061561A NO20061561L (no) 2003-09-10 2006-04-06 Aerosolformuleringer for avlevering av dihydroergotamin til den systemiske sirkulasjon via pulmonaer inhalering

Country Status (7)

Country Link
US (2) US20080118442A1 (no)
EP (1) EP1663159A4 (no)
JP (2) JP2007505136A (no)
AU (2) AU2004272077A1 (no)
CA (1) CA2538237A1 (no)
NO (1) NO20061561L (no)
WO (1) WO2005025506A2 (no)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007505136A (ja) * 2003-09-10 2007-03-08 マツプ・フアーマシユーテイカルズ・インコーポレーテツド ジヒドロエルゴタミンを肺吸入により体循環に送達するためのエアゾール製剤
KR101179393B1 (ko) * 2004-03-23 2012-09-07 노파르티스 아게 제약 조성물
CN101262846A (zh) * 2005-07-15 2008-09-10 Map药物公司 在离散的吸入粒子中结合的多种活性药物成分及其制剂
WO2008097664A1 (en) 2007-02-11 2008-08-14 Map Pharmaceuticals, Inc. Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
WO2009047935A1 (ja) * 2007-10-12 2009-04-16 Ono Pharmaceutical Co., Ltd. 微粒子
AU2009214443B2 (en) 2008-02-13 2013-10-10 Board Of Regents, The University Of Texas System Templated open flocs of anisotropic particles for enhanced pulmonary delivery
KR20110040844A (ko) * 2008-07-11 2011-04-20 맵 파마슈티컬스, 인코포레이티드 에어로졸 약물 전달을 위한 용기
US20100291221A1 (en) * 2009-05-15 2010-11-18 Robert Owen Cook Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
WO2010151804A1 (en) * 2009-06-26 2010-12-29 Map Pharmaceuticals, Inc. Administration of dihydroergotamine mesylate particles using a metered dose inhaler
IN2012DN04858A (no) 2009-12-23 2015-09-25 Map Pharmaceuticals Inc
KR20140042868A (ko) 2011-06-23 2014-04-07 맵 파마슈티컬스, 인코포레이티드 신규한 플루오로에르골린 유사체
SG10201509139QA (en) 2011-12-19 2015-12-30 Map Pharmaceuticals Inc Novel iso-ergoline derivatives
CA2859175A1 (en) 2011-12-21 2013-06-27 Map Pharmaceuticals, Inc. Novel neuromodulatory compounds
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
EP2934529A1 (en) * 2012-12-21 2015-10-28 MAP Pharmaceuticals, Inc. Novel ergoline derivatives and uses thereof
AU2013361337A1 (en) 2012-12-21 2015-07-09 Map Pharmaceuticals, Inc. 8'-Hydroxy-Dihydroergotamine compounds and compositions
CA2895829A1 (en) 2012-12-21 2014-06-26 Map Pharmaceuticals, Inc. Novel methysergide derivatives
WO2014186754A2 (en) 2013-05-16 2014-11-20 Board Of Regents The University Of Texas System Dry solid aluminum adjuvant-containing vaccines and related methods thereof
DK3049059T3 (da) 2013-09-24 2022-01-31 Satsuma Pharmaceuticals Inc Intranasal dhe formulering til behandlingen af hovedpine
JP6712428B2 (ja) 2014-02-04 2020-06-24 コントラフェクト コーポレイション インフルエンザ受動免疫に有用な抗体ならびにその使用のための組成物、組合せおよび方法
MX2017009405A (es) 2015-01-20 2018-01-18 Xoc Pharmaceuticals Inc Compuestos de tipo ergolina y usos de estos.
EP3247357A4 (en) 2015-01-20 2018-07-11 Xoc Pharmaceuticals, Inc Isoergoline compounds and uses thereof
MX2018002895A (es) 2015-09-10 2018-07-06 Impel Neuropharma Inc Dispositivo de administracion nasal en linea.
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
CN108883103A (zh) 2015-12-02 2018-11-23 阿斯特来亚治疗有限责任公司 哌啶基痛敏肽受体化合物
US10047077B2 (en) 2016-04-13 2018-08-14 Skyline Antiinfectives, Inc. Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
US10106521B2 (en) 2016-11-09 2018-10-23 Phloronol, Inc. Eckol derivatives, methods of synthesis and uses thereof
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
WO2018223065A1 (en) 2017-06-01 2018-12-06 Xoc Pharmaceuticals, Inc. Ergoline derivatives for use in medicine
WO2019118393A1 (en) 2017-12-11 2019-06-20 Board Of Regents, The University Of Texas System Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration
JP7317020B2 (ja) 2018-01-05 2023-07-28 インペル ファーマシューティカルズ インコーポレイテッド 精密嗅覚デバイスによるジヒドロエルゴタミンの鼻腔内送達
US10532049B1 (en) 2018-08-27 2020-01-14 Pharmaceutical Industries Limited Parenteral unit dosage form of dihydroergotamine
GB201817868D0 (en) * 2018-11-01 2018-12-19 Nicoventures Trading Ltd Aerosolised formulation
CN120284965A (zh) 2018-12-11 2025-07-11 小蜜橘制药公司 用于治疗或预防头痛的组合物、装置和方法
GB2581431A (en) * 2018-12-11 2020-08-19 Satsuma Pharmaceuticals Inc Compositions, devices, and methods for treating or preventing headaches
CN113874080B (zh) 2019-02-06 2024-09-27 戴斯阿尔法公司 Il-17a调节剂及其用途
EP4031534A1 (en) 2019-09-16 2022-07-27 Dice Alpha, Inc. Il-17a modulators and uses thereof
WO2021133744A1 (en) * 2019-12-23 2021-07-01 Scienture, Inc. Dihydroergotamine mesylate formulations and pre-filled injectors for therapeutic delivery of the same
US12024521B2 (en) 2020-06-30 2024-07-02 Prosetta Biosciences, Inc. Isoquinoline derivatives, methods of synthesis and uses thereof
KR20230169979A (ko) 2021-03-10 2023-12-18 다이스 몰레큘스 에스브이, 인크. 알파 v 베타 6 및 알파 v 베타 1 인테그린 억제제 및 그의 용도
CA3236150A1 (en) 2021-10-22 2023-04-27 Prosetta Biosciences, Inc. Novel host-targeted pan-respiratory antiviral small molecule therapeutics
US20230248724A1 (en) * 2021-10-29 2023-08-10 Sun Pharmaceutical Industries Limited Method of Injecting Dihydroergotamine Into The Body
US11981694B2 (en) 2022-01-03 2024-05-14 Lilac Therapeutics, Inc. Acyclic thiol prodrugs
WO2023129577A1 (en) 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Cyclic thiol prodrugs
CA3253352A1 (en) 2022-03-02 2023-09-07 Mitopower, Inc. NEW PROMEDICINAL PRODUCTS DERIVED FROM NICOTINIC ACID AND RIBOSE
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
GB2636969A (en) 2023-11-24 2025-07-09 Ontrack Therapeutics Ltd Novel crystalline salt forms

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE555319A (no) * 1956-03-21 1900-01-01
US2885427A (en) * 1956-11-15 1959-05-05 Dow Chemical Co Fluorination of trichloroethylene
US3320125A (en) * 1964-04-28 1967-05-16 Merck & Co Inc Inhalation aerosol composition
GB1200886A (en) * 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
US3809294A (en) * 1973-06-27 1974-05-07 American Cyanamid Co Dispensing lung contacting powdered medicaments
BE887518A (fr) * 1980-02-15 1981-08-13 Glaxo Group Ltd Cartothioates d'androstanes
US4311863A (en) * 1980-06-11 1982-01-19 E. I. Du Pont De Nemours & Company Process for the manufacture of 1,1,1,2-tetrafluoroethane
DE3274065D1 (de) * 1981-07-08 1986-12-11 Draco Ab Powder inhalator
EP0072046B1 (en) * 1981-07-24 1986-01-15 FISONS plc Inhalation drugs, methods for their production and pharmaceutical formulations containing them
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
JPS5921613A (ja) * 1982-07-28 1984-02-03 Takeda Chem Ind Ltd 直腸投与製剤
FI70493C (fi) * 1982-08-19 1986-09-19 Stroemberg Oy Ab Vaexelriktare skyddad med avseende pao stighastigheten av stroem och spaenning
JPS6037556A (ja) * 1983-08-10 1985-02-26 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
US4514574A (en) * 1984-01-09 1985-04-30 The Dow Chemical Company Process for separating isomeric mixtures
GB8432063D0 (en) * 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids
GB8501015D0 (en) * 1985-01-16 1985-02-20 Riker Laboratories Inc Drug
US4737384A (en) * 1985-11-01 1988-04-12 Allied Corporation Deposition of thin films using supercritical fluids
NZ221411A (en) * 1986-08-11 1989-10-27 Innovata Biomed Ltd Pharmaceutical compositions containing microcapsules and a surfactant
ATE94782T1 (de) * 1987-12-21 1993-10-15 Union Carbide Corp Verwendung von superkritischen fluessigkeiten als verduenner beim aufspruehen von ueberzuegen.
US5206268A (en) * 1988-08-16 1993-04-27 Burroughs Wellcome Co. Medicaments
US5707634A (en) * 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5776434A (en) * 1988-12-06 1998-07-07 Riker Laboratories, Inc. Medicinal aerosol formulations
US5011678A (en) * 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
DE3905726A1 (de) * 1989-02-24 1990-08-30 Hoechst Ag Druckgaspackung und treibmittel fuer aerosole
CA2058764A1 (en) * 1989-04-28 1990-10-29 Peter D. Hodson Dry powder inhalation device
GB8909891D0 (en) * 1989-04-28 1989-06-14 Riker Laboratories Inc Device
US5238920A (en) * 1989-08-22 1993-08-24 Abbott Laboratories Pulmonary surfactant protein fragments
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
US5178878A (en) * 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5223264A (en) * 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
US5106659A (en) * 1989-10-04 1992-04-21 Nordson Corporation Method and apparatus for spraying a liquid coating containing supercritical fluid or liquified gas
US5118494A (en) * 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
US5126123A (en) * 1990-06-28 1992-06-30 Glaxo, Inc. Aerosol drug formulations
US5292499A (en) * 1990-09-11 1994-03-08 University Of Wales College Of Cardiff Method of preparing medical aerosol formulations including drug dissolved in reverse micelles
MX9203481A (es) * 1990-10-18 1992-07-01 Minnesota Mining & Mfg Formulaciones.
US6006745A (en) * 1990-12-21 1999-12-28 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US5290539A (en) * 1990-12-21 1994-03-01 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US5190029A (en) * 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
US5182097A (en) * 1991-02-14 1993-01-26 Virginia Commonwealth University Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
US5186164A (en) * 1991-03-15 1993-02-16 Puthalath Raghuprasad Mist inhaler
US5182040A (en) * 1991-03-28 1993-01-26 E. I. Du Pont De Nemours And Company Azeotropic and azeotrope-like compositions of 1,1,2,2-tetrafluoroethane
DE4117751A1 (de) * 1991-05-30 1992-12-03 Bayer Ag Verfahren zur isolierung von polycarbonaten
ATE339952T1 (de) * 1991-06-10 2006-10-15 Schering Corp Fluorchlorkohlenwasserstofffreie aerosolformulierungen
US6063910A (en) * 1991-11-14 2000-05-16 The Trustees Of Princeton University Preparation of protein microparticles by supercritical fluid precipitation
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
CA2455115C (en) * 1991-12-12 2008-05-27 Glaxo Group Limited Pharmaceutical aerosol formulation
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US5916540A (en) * 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US5202110A (en) * 1992-01-22 1993-04-13 Virginia Commonwealth University Formulations for delivery of beclomethasone diproprionate by metered dose inhalers containing no chlorofluorocarbon propellants
US5196575A (en) * 1992-02-19 1993-03-23 Hoechst Celanese Corp. Supercritical separation of isomers of functional organic compounds at moderate conditions
US5314682A (en) * 1992-09-21 1994-05-24 Great Lakes Chemical Corp. Ozone friendly sterilant mixture
ATE290864T1 (de) * 1993-03-26 2005-04-15 Franciscus Wilhelmus He Merkus Pharmazeutische zusammensetzungen zur intranasalen verabreichung von dihydroergotamin
US5492688A (en) * 1993-04-28 1996-02-20 The Center For Innovative Technology Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
JP3750872B2 (ja) * 1993-07-14 2006-03-01 株式会社小松製作所 車両用エンジンの過給装置およびその制御方法
EP0728037B1 (en) * 1993-11-08 1999-01-13 The Gillette Company Method of forming particles using a supercritical fluid, aerogel particles formed thereby, and antiperspirants containing aerogel particles
GB9404945D0 (en) * 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
US5508023A (en) * 1994-04-11 1996-04-16 The Center For Innovative Technology Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant
GB9413202D0 (en) * 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
MX9504934A (es) * 1994-12-12 1997-01-31 Morton Int Inc Revestimientos en polvo de pelicula delgada lisa.
US6013245A (en) * 1995-01-26 2000-01-11 Glaxo Group Limited Aerosol formulation containing beclomethasone dipropionate and 1,1,1,2,3,3,3-heptafluoro-n-propane as propellant
US5639475A (en) * 1995-02-03 1997-06-17 Eurand America, Incorporated Effervescent microcapsules
US5607697A (en) * 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
GB9526392D0 (en) * 1995-12-22 1996-02-21 Glaxo Group Ltd Medicaments
US5874029A (en) * 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
US5875776A (en) * 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6503480B1 (en) * 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
US6068832A (en) * 1996-08-29 2000-05-30 Schering Corporation Chlorofluorocarbon-free mometasone furoate aerosol formulations
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US6077539A (en) * 1996-11-12 2000-06-20 Pozen, Inc. Treatment of migraine headache
US6024981A (en) * 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US6200293B1 (en) * 1997-08-27 2001-03-13 Science Incorporated Fluid delivery device with temperature controlled energy source
US5954047A (en) * 1997-10-17 1999-09-21 Systemic Pulmonary Development, Ltd. Methods and apparatus for delivering aerosolized medication
GB9808802D0 (en) * 1998-04-24 1998-06-24 Glaxo Group Ltd Pharmaceutical formulations
GB9810559D0 (en) * 1998-05-15 1998-07-15 Bradford Particle Design Ltd Method and apparatus for particle formation
ES2234266T3 (es) * 1998-07-24 2005-06-16 Jago Research Ag Formulaciones medicas para aerosoles.
US6387410B1 (en) * 1998-09-10 2002-05-14 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US6119853A (en) * 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
US6390291B1 (en) * 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6395299B1 (en) * 1999-02-12 2002-05-28 Biostream, Inc. Matrices for drug delivery and methods for making and using the same
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6858199B1 (en) * 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
WO2001038002A1 (en) * 1999-09-13 2001-05-31 Sheffield Pharmaceuticals, Inc. Aerosol airflow control system and method
US6346323B1 (en) * 1999-10-07 2002-02-12 Sig Pack Systems Ag Multi-layer synthetic film
US6367471B1 (en) * 1999-11-01 2002-04-09 Sheffield Pharmaceuticals, Inc. Internal vortex mechanism for inhaler device
US6620351B2 (en) * 2000-05-24 2003-09-16 Auburn University Method of forming nanoparticles and microparticles of controllable size using supercritical fluids with enhanced mass transfer
US6406681B1 (en) * 2000-08-21 2002-06-18 Aeropharm Technology, Inc. Method of treating a systemic disease
US6514482B1 (en) * 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
JP2005503425A (ja) * 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
US20030198669A1 (en) * 2001-07-05 2003-10-23 R.T. Alamo Ventures I, Llc Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine
US6685951B2 (en) * 2001-07-05 2004-02-03 R. T. Alamo Ventures I, Inc. Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine
GB0117696D0 (en) * 2001-07-20 2001-09-12 Bradford Particle Design Plc Particle information
US20030091513A1 (en) * 2001-10-03 2003-05-15 Mohsen Nahed M. Method to generate water soluble or nonwater soluble in nanoparticulates directly in suspension or dispersion media
US6560907B1 (en) * 2002-01-18 2003-05-13 Thomas Vieweg Cartridge magazine system
US7582284B2 (en) * 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
US20060147389A1 (en) * 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
JP2007505136A (ja) * 2003-09-10 2007-03-08 マツプ・フアーマシユーテイカルズ・インコーポレーテツド ジヒドロエルゴタミンを肺吸入により体循環に送達するためのエアゾール製剤
US9682043B2 (en) * 2003-12-09 2017-06-20 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
WO2006039631A2 (en) * 2004-09-30 2006-04-13 Centocor, Inc. Methods and compositions for treating renal cell carcinoma related pathologies
WO2008076287A2 (en) * 2006-12-13 2008-06-26 Tuel Stephen M Methods of making pharmaceutical components for customized drug products
WO2008097664A1 (en) * 2007-02-11 2008-08-14 Map Pharmaceuticals, Inc. Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile

Also Published As

Publication number Publication date
WO2005025506A2 (en) 2005-03-24
AU2004272077A1 (en) 2005-03-24
WO2005025506A3 (en) 2006-03-16
JP2012116841A (ja) 2012-06-21
EP1663159A4 (en) 2010-06-09
AU2010201070A1 (en) 2010-04-15
US20070253913A1 (en) 2007-11-01
JP2007505136A (ja) 2007-03-08
EP1663159A2 (en) 2006-06-07
US20080118442A1 (en) 2008-05-22
CA2538237A1 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
NO20061561L (no) Aerosolformuleringer for avlevering av dihydroergotamin til den systemiske sirkulasjon via pulmonaer inhalering
US10398673B2 (en) Mast cell stabilizers treatment for systemic disorders
Kumar et al. Intranasal drug delivery: A non-invasive approach for the better delivery of neurotherapeutics
YU36302A (sh) Novi tiotropiumski preparati - koji sadrže prah za inhaliranje
GEP20063876B (en) Pressurised metered dose inhalers containing solutions of beta-2 agonists
SG146649A1 (en) Mucoactive agents for treating a pulmonary disease
PE20030949A1 (es) Formulaciones en aerosol para la administracion pulmonar de medicamentos que producen un efecto sistemico
WO2005025535A3 (en) Methods for preparing pharmaceutical compositions
CN115427076B (zh) 用于治疗冠状病毒感染的人去泛素化酶抑制剂
NO20064161L (no) Farmasoytiske formuleringer for torrpulverinhalatorer omfattende en aktiv ingrediens med lavdoseringsstyrke
CN102740912A (zh) 一种用于产生细小的浓缩气溶胶的方法和设备
RU2005135332A (ru) Назальные фармацевтические композиции и способы их применения
MX2017004476A (es) Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion.
WO2005048985A3 (en) Alpha 1-antitrypsin compositions and treatment methods using such compositions
MX2020011474A (es) Nuevo tratamiento de enfermedades pulmonares intersticiales.
HRP20120286T1 (hr) Kombinacija antikolinergika i inhibitora fosfodiesteraze tip 4 za liječenje respiratornih bolesti
CN115515587A (zh) 用于治疗冠状病毒感染的6’-甲氧基辛可宁-9-醇类
MX2020010977A (es) Procedimientos de tratamiento de infecciones fúngicas.
Lewis et al. New actuators versus old: reasons and results for actuator modifications for HFA solution MDIs
NO20053090L (no) Pulverformulering for innhalering inneholdende tiotropium.
Yang et al. Excipient-free, spray-dried powders for pulmonary aztreonam delivery
JP2016531138A5 (no)
JPH09227373A (ja) 抗インフルエンザウイルス剤
CN111971034A (zh) 一种含格隆铵盐的气雾剂药物组合物及其制备方法与应用
Xu et al. A novel pullulan excipient for inhalable spray-dried powders

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application